Results 241 to 250 of about 375,096 (307)

Dual Covalent Targeting of STING Cysteines 292/309 Disrupts Functional Oligomerization and Enables Potent Antagonist Development

Advanced Science, EarlyView.
We report a rational design strategy for STING antagonists by dual covalent targeting of Cys292/309 in its C‐terminal domain, directly preventing functional oligomerization. Through covalent warhead repurposing, we identified P005091 and revealed its unique dual‐cysteine mechanism.
Yuxuan Zhao, Ling Huang, Wenjing Qin, Bin Zhang, Yang Yang, Xue Chen, Xiaoquan Wang, Weilin Zhou, Feiyang Chen, Zhenyu Li, Liyuan Le, Yiqiu Zhang, Zhen Xiang, Lu Zhang, Fei Wang, Dan Lei, Zi‐zhe Cai, Ying Gao, Yong Chen, Xuecen Wang, Junmin Quan, Shuixing Zhang, Xianzhang Bu, Xin Yue   +23 more
wiley   +1 more source

EEPD1 Inhibition Unleashes Antitumor Immunity in Colorectal Cancer by Activating the cGAS‐STING Pathway

Advanced Science, EarlyView.
In colorectal cancer, high expression of the DNA repair protein EEPD1 correlates with immune exclusion and poor prognosis. This study demonstrates that EEPD1 depletion induces genomic instability, leading to cytosolic DNA accumulation and subsequent activation of the cGAS‐STING‐type I interferon pathway. This cascade remodels the tumor microenvironment
Liyun Huo, Chong Wu, Xiaobo Li, Caina Ma, Jiamin Huang, Zishuo Chen, Weiling He, Tianyu Tao, Weijing Zhang   +8 more
wiley   +1 more source

Autoantibody landscape and functional role of anti-C-C motif chemokine receptor 8 autoantibodies in systemic sclerosis: post-hoc analysis of a B-cell depletion trial. [PDF]

Nat Commun
Matsuda KM, Chen YY, Ebata S, Iwadoh K, Kotani H, Kuzumi A, Yoshizaki-Ogawa A, Lan CE, Yu HS, Sumida H, Sato S.   +10 more
europepmc   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Multicystic Interstitial Lung Disease Due to a Novel Biallelic C-C Chemokine Receptor Type 2 Variant. [PDF]

Pediatr Pulmonol
Herkner M, Rapp C, Graeber SY, Marx C, Rambuscheck C, Reu-Hofer S, Emiralioglu N, Kiper N, Gilea AI, Notaroberto I, Baruffini E, Temmesfeld-Wollbrück B, Klein C, Wen H, Stahl M, Griese M, Gothe F.   +16 more
europepmc   +1 more source

CCR5 Utilization of Transmitted and Early Founder HIV-1 Envelopes and the Sensitivity to Small CCR5 Inhibitors [PDF]

, 2008
Hu, Q, Huang, X, Shattock, RJ
core  

C-C chemokine receptor type 5 activation stimulates adipocyte differentiation through ERK-dependent pathway. [PDF]

Int J Med Sci
Chen LK, Chen CW, Wu SY, Liu SY, Wu LY, Chang CJ, Sy LB, Juan CC.   +7 more
europepmc   +1 more source

Hsa-miR-100-5p promotes the development and progression of gastric cancer through targeted atypical chemokine receptor 3. [PDF]

Int J Clin Exp Pathol
Wang XL, Jiang JC, Song JY, Ni JY, Song L, Xiao JZ, Fu D, Chen ZY, Cao YF.   +8 more
europepmc   +1 more source

Extended repertoire of CXC chemokines acting as agonists and antagonists of the human and murine atypical chemokine receptor ACKR2. [PDF]

J Leukoc Biol
Luís R, Volkman BF, Szpakowska M, Chevigné A.   +3 more
europepmc   +1 more source

Estradiol Promotes Myelin Repair in the Spinal Cord of Female Mice in a CXCR4 Chemokine Receptor-Independent Manner. [PDF]

Int J Mol Sci
Bardy-Lagarde M, Asbelaoui N, Schumacher M, Ghoumari AM.   +3 more
europepmc   +1 more source